logo

AMRX

Amneal·NASDAQ
--
--(--)
--
--(--)
2.27 / 10
Underperform

AMRX's fundamental quality is rated weak (2.3/10). Key concerns include a Days Sales Outstanding of 101.7 days (high collection risk) and modest YoY revenue growth of 6.83%. Favorable aspects are a positive Interest Coverage ratio (1.45) and relatively strong Profit-MV and Cash-MV scores, but these do not offset the overall weakness, leading to an 'Underperform' stance.

Fundamental(2.27)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value0.74
Score2/3
Weight18.84%
1M Return7.73%
Total operating revenue (YoY growth rate %)
Value6.83
Score1/3
Weight-1.40%
1M Return-0.79%
Days sales outstanding
Value101.72
Score0/3
Weight-8.50%
1M Return-5.18%
Profit-MV
Value0.17
Score2/3
Weight19.19%
1M Return8.45%
Net income-Revenue
Value-1.67
Score2/3
Weight19.21%
1M Return8.45%
PB-ROE
Value-0.19
Score1/3
Weight23.37%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value1.45
Score2/3
Weight-1.92%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value6.83
Score1/3
Weight-1.35%
1M Return-0.76%
Asset-MV
Value-0.50
Score0/3
Weight13.71%
1M Return5.75%
Cash-MV
Value0.32
Score2/3
Weight18.87%
1M Return8.41%
Is AMRX undervalued or overvalued?
  • AMRX scores 2.27/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, 1.96% net margin, 1352.46 P/E ratio, -108.23 P/B ratio, and 102.33% earnings growth, these metrics solidify its Underperform investment rating.